Back to top

crispr: Archive

Zacks Equity Research

BEAM Focuses on Developing Gene Drug for Growth

While BEAM's pipeline candidates are in early-stage clinical studies, their development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.

PFEPositive Net Change VRTXPositive Net Change BEAMPositive Net Change CRSPPositive Net Change

Zacks Equity Research

Intellia (NTLA), Regeneron Expand Deal for Gene-Editing Therapies

Intellia (NTLA) expands partnership with Regeneron, to develop potential treatments for neurological and muscular diseases.

REGNPositive Net Change ANIKPositive Net Change NTLAPositive Net Change ANVSPositive Net Change

Zacks Equity Research

Vertex (VRTX) Gets Positive CHMP Opinion for Kaftrio Expanded Use

Vertex's (VRTX) Kaftrio gets a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for extended use to treat younger age groups of two to five years old with cystic fibrosis.

VRTXPositive Net Change ANIKPositive Net Change CRSPPositive Net Change ANVSPositive Net Change